Similar articles

• A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

  Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E. Thomsen OO, et al. N Engl J Med. 1998 Aug 6;339(6):370-4. doi: 10.1056/NEJM199808063390603. N Engl J Med. 1998. PMID: 9691103 Clinical Trial.
• Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?

  Feagan BG, Sandborn WJ. Feagan BG, et al. Rev Gastroenterol Disord. 2002;2 Suppl 2:S9-15. Rev Gastroenterol Disord. 2002. PMID: 12478239 Review.
• Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.

  Mantzaris GJ, Petraki K, Sfakianakis M, Archavlis E, Christidou A, Chadio-Iordanides H, Triadaphyllou G. Mantzaris GJ, et al. Clin Gastroenterol Hepatol. 2003 Mar;1(2):122-8. doi: 10.1053/cgh.2003.50015. Clin Gastroenterol Hepatol. 2003. PMID: 15017504 Clinical Trial.
• Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.

  Bauditz J, Lochs H, Schreiber S. Bauditz J, et al. N Engl J Med. 1998 Jan 29;338(5):334. doi: 10.1056/NEJM199801293380515. N Engl J Med. 1998. PMID: 9446035 No abstract available.
• [Drug therapy of Crohn disease].

  Niemelä S. Niemelä S. Duodecim. 2001;117(8):807-14. Duodecim. 2001. PMID: 12116446 Review. Finnish. No abstract available.